FindTrial
Sign In

Clinical evaluation of using autologous dendritic cell as adjuvant therapy to poor response tuberculosis: a randomized controlled trial

Clinical evaluation of using autologous dendritic cell as adjuvant therapy to poor response tuberculosisa: a randomized controlled trial

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009606
Enrollment
Unknown
Registered
2016-10-26
Start date
2019-03-27
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculosis

Interventions

immunotherapy group:DC immunotherapy group plus standard chemotheraphy
control group:standard chemotherapy

Sponsors

Shanghai Public Health Clinical Center Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. AFB positive, meet diagnostic criteria of Chinese TB guidelines. Sputum AFB positive after 5 months Anti-TB chemotheraphy; 2. Aged 18-65 years; 3. Have fixed address, can be followed up; 4. Written informed consent obtained.

Exclusion criteria

Exclusion criteria: 1. Severe heart disease; severe malnutrition; immunosuppressive therapy; renal dysfunction; diabetes; 2. Severe side effect during TB treatment; 3. History of severe hypersensitivity/allergic shock; () 4. Women during pregnancy and lactation; 5. Severe mental disease; 6. Any other situation that is considered not suitable for this study.

Design outcomes

Primary

MeasureTime frame
sputum AFB conversion time;—

Secondary

MeasureTime frame
immune activity of T cell;—

Countries

China

Contacts

Public ContactLu Shuihua

Shanghai Public Health Clinical Center Affiliated to Fudan University

tubercle@shaphc.org+86 18930811818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026